+

WO2004078130A3 - Proteines d'interaction posh et procedes connexes - Google Patents

Proteines d'interaction posh et procedes connexes Download PDF

Info

Publication number
WO2004078130A3
WO2004078130A3 PCT/US2004/006308 US2004006308W WO2004078130A3 WO 2004078130 A3 WO2004078130 A3 WO 2004078130A3 US 2004006308 W US2004006308 W US 2004006308W WO 2004078130 A3 WO2004078130 A3 WO 2004078130A3
Authority
WO
WIPO (PCT)
Prior art keywords
posh
related methods
interacting proteins
posh interacting
application
Prior art date
Application number
PCT/US2004/006308
Other languages
English (en)
Other versions
WO2004078130A2 (fr
Inventor
Daniel N Taglicht
Iris Alroy
Yuval Reiss
Liora Yaar
Danny Ben-Avraham
Shmuel Tuvia
Tsvika Greener
Original Assignee
Proteologics Inc
Daniel N Taglicht
Iris Alroy
Yuval Reiss
Liora Yaar
Danny Ben-Avraham
Shmuel Tuvia
Tsvika Greener
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/035712 external-priority patent/WO2004098492A2/fr
Priority claimed from PCT/US2004/003600 external-priority patent/WO2004073609A2/fr
Priority to AU2004218430A priority Critical patent/AU2004218430A1/en
Priority to EP04716503A priority patent/EP1646644A4/fr
Priority to CA002517525A priority patent/CA2517525A1/fr
Priority to US10/547,845 priority patent/US20060286630A1/en
Application filed by Proteologics Inc, Daniel N Taglicht, Iris Alroy, Yuval Reiss, Liora Yaar, Danny Ben-Avraham, Shmuel Tuvia, Tsvika Greener filed Critical Proteologics Inc
Priority to PCT/US2004/010582 priority patent/WO2004089302A2/fr
Priority to US10/551,587 priority patent/US20070122807A1/en
Priority to EP04777768A priority patent/EP1651226B1/fr
Priority to DE602004025708T priority patent/DE602004025708D1/de
Priority to PCT/US2004/021900 priority patent/WO2005007141A2/fr
Priority to AT04777768T priority patent/ATE458485T1/de
Publication of WO2004078130A2 publication Critical patent/WO2004078130A2/fr
Priority to US11/330,500 priority patent/US7659277B2/en
Publication of WO2004078130A3 publication Critical patent/WO2004078130A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)

Abstract

L'invention porte sur de nouveaux complexes de polypeptides POSH et sur des protéines associées à POSH, ainsi que sur des procédés et sur des compositions permettant de traiter des maladies associées à POSH telles que des maladies virales, le cancer et des troubles neurologiques.
PCT/US2004/006308 2003-03-03 2004-03-02 Proteines d'interaction posh et procedes connexes WO2004078130A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2004218430A AU2004218430A1 (en) 2003-03-03 2004-03-02 Posh interacting proteins and related methods
EP04716503A EP1646644A4 (fr) 2003-03-03 2004-03-02 Proteines d'interaction posh et procedes connexes
CA002517525A CA2517525A1 (fr) 2003-03-03 2004-03-02 Proteines d'interaction posh et procedes connexes
US10/547,845 US20060286630A1 (en) 2003-03-03 2004-03-02 Posh interacting proteins and related methods
PCT/US2004/010582 WO2004089302A2 (fr) 2003-04-03 2004-04-05 Polypeptides posh, complexes et procedes correspondants
US10/551,587 US20070122807A1 (en) 2003-04-03 2004-04-05 Posh polypeptides, complexes and related methods
AT04777768T ATE458485T1 (de) 2003-07-11 2004-07-09 Ubiquitin-ligase-hemmer und verwandte verfahren
EP04777768A EP1651226B1 (fr) 2003-07-11 2004-07-09 Inhibiteurs de l'ubiquitine ligase et methodes associees
PCT/US2004/021900 WO2005007141A2 (fr) 2003-07-11 2004-07-09 Inhibiteurs de l'ubiquitine ligase et methodes associees
DE602004025708T DE602004025708D1 (de) 2003-07-11 2004-07-09 Ubiquitin-ligase-hemmer und verwandte verfahren
US11/330,500 US7659277B2 (en) 2003-07-11 2006-01-11 Ubiquitin ligase inhibitors and methods related thereto

Applications Claiming Priority (42)

Application Number Priority Date Filing Date Title
US45143703P 2003-03-03 2003-03-03
US60/451,437 2003-03-03
US45228403P 2003-03-05 2003-03-05
US60/452,284 2003-03-05
US45576003P 2003-03-19 2003-03-19
US60/455,760 2003-03-19
US45664003P 2003-03-20 2003-03-20
US60/456,640 2003-03-20
US46052603P 2003-04-03 2003-04-03
US60/460,526 2003-04-03
US46079203P 2003-04-04 2003-04-04
US60/460,792 2003-04-04
US46428503P 2003-04-21 2003-04-21
US60/464,285 2003-04-21
US46946203P 2003-05-09 2003-05-09
US60/469,462 2003-05-09
US47137803P 2003-05-15 2003-05-15
US60/471,378 2003-05-15
US47232703P 2003-05-20 2003-05-20
US60/472,327 2003-05-20
US47470603P 2003-05-30 2003-05-30
US60/474,706 2003-05-30
US47582503P 2003-06-03 2003-06-03
US60/475,825 2003-06-03
US47931703P 2003-06-17 2003-06-17
US60/479,317 2003-06-17
US48037603P 2003-06-19 2003-06-19
US48021503P 2003-06-19 2003-06-19
US60/480,376 2003-06-19
US60/480,215 2003-06-19
US49386003P 2003-08-08 2003-08-08
US60/493,860 2003-08-08
US49863403P 2003-08-28 2003-08-28
US60/498,634 2003-08-28
US50393103P 2003-09-16 2003-09-16
US60/503,931 2003-09-16
USPCT/US03/35712 2003-11-10
PCT/US2003/035712 WO2004098492A2 (fr) 2002-11-11 2003-11-10 Processus associes au reseau trans-golgi et methodes et compositions associees
USPCT/US04/03600 2004-02-05
PCT/US2004/003600 WO2004073609A2 (fr) 2003-02-05 2004-02-05 Kinases associees a posh et methodes correspondantes
US54989604P 2004-03-02 2004-03-02
US60/549,896 2004-03-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/330,500 Continuation-In-Part US7659277B2 (en) 2003-07-11 2006-01-11 Ubiquitin ligase inhibitors and methods related thereto

Publications (2)

Publication Number Publication Date
WO2004078130A2 WO2004078130A2 (fr) 2004-09-16
WO2004078130A3 true WO2004078130A3 (fr) 2006-01-12

Family

ID=36091550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006308 WO2004078130A2 (fr) 2003-03-03 2004-03-02 Proteines d'interaction posh et procedes connexes

Country Status (4)

Country Link
EP (1) EP1646644A4 (fr)
AU (1) AU2004218430A1 (fr)
CA (1) CA2517525A1 (fr)
WO (1) WO2004078130A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE458485T1 (de) 2003-07-11 2010-03-15 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
US20060188890A1 (en) * 2003-10-31 2006-08-24 Proteologics, Inc. Ubiquitin-based protein interaction assays and related compositions
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
WO2011062962A2 (fr) * 2009-11-17 2011-05-26 The Trustees Of The University Of Pennsylvania Dégron smndelta7 : nouvelles compositions et procédés d'utilisation
EP2471548A1 (fr) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA contre la Cbl-b et optionnellement l'IL2 et l'IL12 pour l'utilisation dans le traitement du cancer
CN106133136A (zh) * 2014-01-17 2016-11-16 松尾洋孝 痛风发病关联分子、尿酸关联疾病素质与炎症关联疾病素质的评价方法及评价试剂盒、检查体及药物
WO2017139746A1 (fr) * 2016-02-11 2017-08-17 Mark Daniels Biomolécules complexes et micelles amphiphiles inhibitrices de posh
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089302A2 (fr) * 2003-04-03 2004-10-21 Proteologics, Inc. Polypeptides posh, complexes et procedes correspondants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FIGUEROA C ET AL: "Akt2 Negatively Regulates Assembly of the POSH-MLK-JNK Signaling Complex.", THE J BIO CHEM., vol. 278, no. 48, 28 November 2003 (2003-11-28), pages 47922 - 47927, XP002996244 *
See also references of EP1646644A4 *
TAPON N ET AL: "A new Rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-kappaB signalling pathways.", THE EMBO JOURNAL., vol. 17, no. 5, 1998, pages 1395 - 1404, XP002250463 *
XU Z ET AL: "POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis.", J EMBO., vol. 22, no. 2, January 2003 (2003-01-01), pages 252 - 261, XP002985544 *

Also Published As

Publication number Publication date
AU2004218430A1 (en) 2004-09-16
EP1646644A4 (fr) 2007-05-16
EP1646644A2 (fr) 2006-04-19
WO2004078130A2 (fr) 2004-09-16
CA2517525A1 (fr) 2004-09-16

Similar Documents

Publication Publication Date Title
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2004080425A3 (fr) Composes polypeptidiques permettant d'inhiber l'angiogenese et la croissance tumorale
WO2005049593A3 (fr) Promoteurs de l'apoptose contenant n-acylsulfonamide
WO2003029209A3 (fr) Composes chimiques
WO2003033720A8 (fr) Proteine a base de variants de tnf-alpha pour le traitement de troubles associes au tnf-alpha
WO2003080582A3 (fr) Derives de fredericamycine
WO2005030144A3 (fr) Composes de pyrrolopyridazine, et procedes pour les utiliser pour traiter des troubles de proliferation
WO2007059008A3 (fr) Indenoisoquinolines n-substituees et leur synthese
WO2003051886A8 (fr) Derives de pyrazolopyridazine
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2007059341A3 (fr) Modulateurs de la proteine kinase a base de pyrazolothiazole
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
WO2000066528A3 (fr) Novel quinones utilisees dans le traitements de maladies
WO2004002418A3 (fr) Compositions et procedes comprenant des antagonistes des recepteurs actives de proteines
WO2004098524A3 (fr) Complexes de platine a lipides et leurs procedes d'utilisation
WO2005030794A3 (fr) Derives d'hemiasterline et utilisations de ces derives
WO2004078130A3 (fr) Proteines d'interaction posh et procedes connexes
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2006019982A3 (fr) Composes modulateurs de pin1 et leurs procedes d'utilisation
WO2006053315A3 (fr) Methodes et compositions de traitement de maladies proliferatives cellulaires
WO2005037236A3 (fr) Nouveaux polypeptides associes a la proteine de choc thermique 20 et utilisations
WO2004101766A3 (fr) Compositions a base de grp94 et procedes d'utilisation associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2517525

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 170621

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004218430

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004716503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 542747

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004218430

Country of ref document: AU

Date of ref document: 20040302

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004218430

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11330500

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004716503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006286630

Country of ref document: US

Ref document number: 10547845

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10547845

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11330500

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载